RS4:11 Cells
USD$395.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | The RS4:11 cell line is derived from a 32-year-old female patient with relapsed acute lymphoblastic leukemia (ALL) characterized by the t(4:11)(q21:q23) chromosomal translocation. This translocation results in the formation of the **KMT2A-AFF1 (formerly MLL-AF4)** fusion gene, which is a hallmark of this leukemia subtype. RS4:11 cells exhibit a biphenotypic profile, co-expressing both B-cell and monocytic markers, reflecting the mixed-lineage characteristics associated with this genetic rearrangement. The cell line is widely used as a model for understanding the biology of KMT2A-rearranged leukemias, which are associated with aggressive disease and poor prognosis. RS4:11 cells display features typical of pre-B lymphoblasts, including expression of markers such as CD19, HLA-DR, and terminal deoxynucleotidyl transferase (TdT), along with rearranged immunoglobulin heavy and light chain genes. Interestingly, upon treatment with differentiation-inducing agents like phorbol esters, RS4:11 cells adopt a monocyte-like phenotype, highlighting their lineage plasticity. This characteristic makes the cell line particularly valuable for studying the molecular drivers of differentiation and lineage commitment in leukemia. Genetically, the t(4:11) translocation disrupts the **KMT2A gene at 11q23**, fusing it with **AFF1 (AF4)** on 4q21, leading to a chimeric protein that aberrantly regulates gene expression, including Hox genes involved in hematopoietic development. RS4:11 cells have also been used to study secondary mutations, such as those in **FLT3**, which contribute to leukemogenesis and treatment resistance. The cell line serves as a robust preclinical model for testing targeted therapies, including inhibitors of the KMT2A-AFF1 interaction and agents aimed at associated signaling pathways. |
|---|---|
| Organism | Human |
| Tissue | Bone marrow |
| Disease | Adult B acute lymphoblastic leukemia |
| Synonyms | RS4-11, RS4;11, RS 4;11, RS(4;11), RS411 |
Characteristics
| Age | 32 years |
|---|---|
| Gender | Female |
| Ethnicity | Caucasian |
| Morphology | Lymphoblast-like |
| Growth properties | Suspension |
Regulatory Data
| Citation | RS4:11 (Cytion catalog number 305360) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_0093 |
Biomolecular Data
| MSI-status | Instable, high MSI reported |
|---|
Handling
| Culture Medium | Alpha MEM, w: 2.0 mM stable Glutamine, w: Ribonucleosides, w: Deoxyribonucleosides, w: 1.0 mM Sodium pyruvate, w: 2.2g/L NaHCO3, w/o: Ascorbic acid (GIBCO, Catalog No. A1049001. We do not supply this product; please consider other suppliers. Please let us know if you need further assistance.) |
|---|---|
| Supplements | Supplement the medium with 20% heat-inactivated FBS |
| Seeding density | Seed cultures at 3-5 x 105 cells/mL |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305360-311024 | Certificate of Analysis | 23. May. 2025 | 305360 |